Lynparza’s narrow label in front-line prostate cancer reflects a “shift in the regulatory and clinical perception” of the drug and others like it, collectively known as PARP inhibitors, wrote SVB Securities analyst Andrew Berens in a Wednesday note.
Several PARP inhibitors are available to treat ovarian, breast, pancreatic and prostate tumors. They’re typically used as “maintenance” therapies — meant to slow cancer’s return after a tumor is surgically removed or eliminated by other drugs. In recent years, they have shown potential in earlier lines of care, too.
